Generic Narcan Availability
Last updated on Apr 10, 2025.
Narcan is a brand name of naloxone, approved by the FDA in the following formulation(s):
NARCAN (naloxone hydrochloride - injectable;injection)
-
Manufacturer: ADAPT
Approved Prior to Jan 1, 1982
Strength(s): 0.02MG/ML (discontinued) [RLD], 0.4MG/ML (discontinued) [RLD] -
Manufacturer: ADAPT
Approval date: June 14, 1982
Strength(s): 1MG/ML (discontinued) [RLD]
NARCAN (naloxone hydrochloride - spray, metered;nasal)
-
Manufacturer: EMERGENT
Approval date: January 24, 2017
Strength(s): 2MG/SPRAY (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Narcan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Nasal drug products and methods of their use
Patent 9,480,644
Issued: November 1, 2016
Inventor(s): Crystal Roger & Weiss Michael Brenner
Assignee(s): Opiant Pharmaceuticals, Inc.Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.
Patent expiration dates:
- March 16, 2035✓✓✓
- March 16, 2035
-
Nasal drug products and methods of their use
Patent 9,707,226
Issued: July 18, 2017
Inventor(s): Keegan; Fintan et al.
Assignee(s): ADAPT PHARMA LIMITED (Dublin, IE); OPIANT PHARMACEUTICALS (Santa Monica, CA)Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.
Patent expiration dates:
- March 16, 2035✓✓✓
- March 16, 2035
More about Narcan (naloxone)
- Narcan consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (5)
- Drug images
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antidotes
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
